Condition: Urothelial Carcinoma · Muscle Invasive Bladder Urothelial Carcinoma · Non-Muscle Invasive Bladder Urothelial Carcinoma · Sponsor: Fox Chase Cancer Center
This trial aims at investigating the diagnostic ability of a combined diagnostic panel including systematic endoscopic evaluation (SEE), blood-based ctDNA assay, and urine-based cfDNA assay to predict the presence of residual tumor remaining in the bladder at cystectomy. Patients who are planned for cystectomy due to bladder cancer will be considered for enrollment based on inclusion and exclusion criteria.
This description comes directly from the study's public registry record.
Alexander Kutikov, M.D. · 215-728-3096 · alexander.kutikov@fccc.edu
Always discuss trial participation with your own doctor first.
| University of Nebraska Medical Center | Omaha, Nebraska, United States | Recruiting |
| Fox Chase Cancer Center | Philadelphia, Pennsylvania, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06396533